cilostazol has been researched along with Brugada Syndrome in 3 studies
Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome." | 7.79 | Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. ( Antzelevitch, C; Koncz, I; Szél, T, 2013) |
| "Our study identifies milrinone as a more potent alternative to cilostazol for reversing the repolarization defects responsible for the electrocardiographic and arrhythmic manifestations of Brugada syndrome." | 3.79 | Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome. ( Antzelevitch, C; Koncz, I; Szél, T, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Szél, T | 1 |
| Koncz, I | 1 |
| Antzelevitch, C | 1 |
| Hasegawa, K | 1 |
| Ashihara, T | 1 |
| Kimura, H | 1 |
| Jo, H | 1 |
| Itoh, H | 1 |
| Yamamoto, T | 1 |
| Aizawa, Y | 1 |
| Horie, M | 1 |
| Yodogawa, K | 1 |
| Morita, N | 1 |
| Kobayashi, Y | 1 |
| Takayama, H | 1 |
| Ohara, T | 1 |
| Katoh, T | 1 |
| Takano, T | 1 |
3 other studies available for cilostazol and Brugada Syndrome
| Article | Year |
|---|---|
Cellular mechanisms underlying the effects of milrinone and cilostazol to suppress arrhythmogenesis associated with Brugada syndrome.
Topics: Action Potentials; Animals; Brugada Syndrome; Cilostazol; Disease Models, Animal; Dogs; Drug Therapy | 2013 |
Long-term pharmacological therapy of Brugada syndrome: is J-wave attenuation a marker of drug efficacy?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; C | 2014 |
High-frequency potentials developed in wavelet-transformed electrocardiogram as a novel indicator for detecting Brugada syndrome.
Topics: Action Potentials; Adrenergic beta-Agonists; Adult; Aged; Anti-Arrhythmia Agents; Brugada Syndrome; | 2006 |